Susquehanna International Group’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-221,719
| Closed | -$282K | – | 13745 |
|
|
2023
Q3 | $282K | Buy |
+221,719
| New | +$194K | ﹤0.01% | 9489 |
|
|
2022
Q3 | – | Sell |
-10,867
| Closed | -$12.3K | – | 14448 |
|
|
2022
Q2 | $12K | Sell |
10,867
-151,779
| -93% | -$193K | ﹤0.01% | 12483 |
|
|
2022
Q1 | $333K | Sell |
162,646
-209,915
| -56% | -$499K | ﹤0.01% | 10021 |
|
|
2021
Q4 | $1.07M | Buy |
372,561
+235,696
| +172% | +$872K | ﹤0.01% | 7117 |
|
|
2021
Q3 | $580K | Buy |
+136,865
| New | +$611K | ﹤0.01% | 8989 |
|
|
2021
Q2 | – | Sell |
-43,680
| Closed | -$210K | – | 13475 |
|
|
2021
Q1 | $203K | Sell |
43,680
-93,945
| -68% | -$426K | ﹤0.01% | 11402 |
|
|
2020
Q4 | $454K | Buy |
137,625
+35,069
| +34% | +$133K | ﹤0.01% | 8499 |
|
|
2020
Q3 | $339K | Buy |
102,556
+47,835
| +87% | +$176K | ﹤0.01% | 8468 |
|
|
2020
Q2 | $184K | Sell |
54,721
-216,959
| -80% | -$1.03M | ﹤0.01% | 9120 |
|
|
2020
Q1 | $1.04M | Buy |
271,680
+26,387
| +11% | +$123K | ﹤0.01% | 5316 |
|
|
2019
Q4 | $1.48M | Buy |
245,293
+187,876
| +327% | +$1.28M | ﹤0.01% | 4824 |
|
|
2019
Q3 | $434K | Buy |
57,417
+46,185
| +411% | +$521K | ﹤0.01% | 7597 |
|
|
2019
Q2 | $152K | Sell |
11,232
-87,465
| -89% | -$1.01M | ﹤0.01% | 9364 |
|
|
2019
Q1 | $535K | Sell |
98,697
-111,997
| -53% | -$545K | ﹤0.01% | 6142 |
|
|
2018
Q4 | $625K | Sell |
210,694
-118,568
| -36% | -$649K | ﹤0.01% | 5595 |
|
|
2018
Q3 | $2.69M | Buy |
329,262
+208,871
| +173% | +$1.6M | ﹤0.01% | 3527 |
|
|
2018
Q2 | $1.17M | Buy |
+120,391
| New | +$1.23M | ﹤0.01% | 5005 |
|
|
2018
Q1 | – | Sell |
-170,533
| Closed | -$1.84M | – | 10407 |
|
|
2017
Q4 | $2.13M | Buy |
+170,533
| New | +$1.95M | ﹤0.01% | 3796 |
|
Susquehanna International Group's ZYNE Position: Q4 2023 in Review
Susquehanna International Group sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q4 2023, closing a stake of 221,719 shares — an estimated $282K sold.
Susquehanna International Group first reported a position in ZYNE in Q4 2017 and held it in 18 quarters. The position peaked at $2.69M in Q3 2018. 0 funds tracked by Wall St. Rank hold ZYNE as of Q4 2023.
- Susquehanna International Group reported no remaining Zynerba Pharmaceuticals, Inc position as of Q4 2023 after selling out during the quarter.
- Susquehanna International Group sold 221,719 Zynerba Pharmaceuticals, Inc shares in Q4 2023, an estimated $282K.
- Susquehanna International Group first reported a position in Zynerba Pharmaceuticals, Inc in Q4 2017 and held it in 18 quarters.
- Susquehanna International Group's Zynerba Pharmaceuticals, Inc position peaked at $2.69M in Q3 2018.
- 0 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q4 2023.
Based on Susquehanna International Group's 13F filing for Q4 2023, filed 14 Feb 2024.